MS Betaferon study
May 8, 2012
RESULTS from the 21-year
Betaferon Long-term Follow-up
Study have shown that patients
with multiple sclerosis treated
earlier with Betaferon 250 ug
(interferon beta-1b) had a 46.8%
risk reduction in the rate of death
at the long-term follow-up, compared
with patients receiving placebo for
up to the first five years of treatment.
Published in Neurology, the study
was the longest assessment of any
MS treatment and according to
lead author of the study, Dr
Douglas Goodin, Professor of
Neurology, University of California,
San Francisco, strongly supported
the “practice of starting effective
disease-modifying therapy early in
the course of MS”.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 May 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 May 12